- Liz Highleyman | 06 January 2015
ARC-520, a novel therapy
using short interfering RNA, appeared safe and was associated with a reduction
in hepatitis B surface antigen levels in people with chronic hepatitis B taking
entecavir, according to phase ...
- Liz Highleyman | 22 December 2014
A combination of entecavir plus tenofovir effectively
suppressed hepatitis B virus (HBV) in people with resistance to other
antivirals, according to results from the European ENTEBE study presented at
the American Association for ...
- Liz Highleyman | 18 December 2014
An
estimated 813,000 people with diagnosed hepatitis C in the US have undergone
liver disease staging and meet the 'highest' or 'high' priority criteria for
immediate treatment, according to an analysis presented at ...
- Liz Highleyman | 18 December 2014
Nearly one-third of chronic hepatitis C patients
with liver cirrhosis and 12% with advanced fibrosis progressed to
decompensation within five years, and 23% and 11%, respectively, died,
according to a study presented at ...
- Liz Highleyman | 10 December 2014
Difficult-to-treat hepatitis C patients with
liver cirrhosis who were not cured with a prior course of first-generation HCV
protease inhibitors had a sustained response rate of 96-97% when re-treated
with sofosbuvir/ledipasvir with ribavirin ...
- Liz Highleyman | 02 December 2014
An interferon-free
regimen of sofosbuvir plus ledipasvir (Harvoni)
taken with ribavirin for 12 or 24 weeks led to sustained virological response
in nearly all HCV genotype 1patients
with fibrosis or less-advanced liver cirrhosis, researchers ...
- Liz Highleyman | 02 December 2014
Regimens containing sofosbuvir
(Sovaldi) – including sofosbuvir plus
simeprevir (Olysio) – work well for people
with hepatitis C genotype 1 in real-world use, which to date has included some
of the patients most urgently ...
- Liz Highleyman | 27 November 2014
Several presentations
at the American Association for the Study of Liver Diseases (AASLD) Liver
Meeting this month in Boston focused on treating hepatitis C recurrence in
liver transplant recipients, one of the most ...
- Liz Highleyman | 27 November 2014
AbbVie's 3D regimen (newly
named Viekirax + Exviera)
demonstrated a sustained
virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation
who had not yet developed advanced liver fibrosis ...
- Liz Highleyman | 25 November 2014
Most people with chronic hepatitis B who are
treated with tenofovir for eight years continued to maintain viral suppression,
researchers reported at the American
Association for the Study of Liver Diseases (AASLD) Liver ...
- Liz Highleyman | 25 November 2014
An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi),
taken for 12 weeks, produced sustained virological response rates of 90% for
previously untreated patients and 86% for prior non-responders with hepatitis C
virus ...
- Liz Highleyman | 21 November 2014
AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir
plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both
produced good sustained virological response rates for most people with ...
- Liz Highleyman | 19 November 2014
A 12-week oral combination
of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high
sustained virological response rates for people with difficult-to-treat HCV
genotype 3 and other genotypes, according to phase 2 study ...
- Liz Highleyman | 17 November 2014
People with chronic
hepatitis B virus (HBV) infection are more likely to experience favourable
treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss,
if they add pegylated interferon to tenofovir – ...
- Liz Highleyman | 13 November 2014
An all-oral regimen of
grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without
ribavirin for 12 weeks, demonstrated high sustained virological response (SVR) rates
for treatment-naive and treatment-experienced people with genotype 1 hepatitis
C ...
- Liz Highleyman | 13 November 2014
[Editor's Note: this article previously stated
that the PEARL-I trial tested the AbbVie 3D Viekira Pak
regimen for HCV genotype 4. In actuality, the study used
the 2D regimen consisting of the paritaprevir coformulation
without dasabuvir. The article has been corrected.]
Sofosbuvir/ledipasvir without
ribavirin and ...
- Liz Highleyman | 12 November 2014
An oral regimen of
sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C
patients with decompensated cirrhosis, the most advanced stage of liver
disease, according to a presentation on Tuesday at ...
- Liz Highleyman | 12 November 2014
People with HIV – most of whom had hepatitis B
or C co-infection – generally had good outcomes after liver transplantation due
to hepatocellular carcinoma (HCC), with five-year survival rates similar to
those ...
- Liz Highleyman | 11 November 2014
Only 15% of US veterans have been tested for hepatitis B virus (HBV)
infection, and among those who tested positive just one-quarter received
antiviral treatment and 13% were screened for liver cancer ...
- Liz Highleyman | 11 November 2014
A 12-week all-oral
regimen of daclatasvir, asunaprevir and beclabuvir, with or
without ribavirin, cured 86 to 90% of genotype 1 hepatitis C patients with
cirrhosis in the phase 3 UNITY-2 trial, while the ...